National Bank of Fujairah achieves two ISO certifications - Middle East Business News and Information
Dubai: Reaffirming National Bank of Fujairah (NBF)'s commitment to operational excellence across its business, the bank has achieved certification for two global quality standards. The certifications include ISO 27001:2022 in Information Security Management System and ISO 9001:2015 in Quality Management System.
Commenting on the certifications, Mahendra Dhillon, Chief Operations and Technology Officer at NBF, said: 'This accomplishment reflects NBF's unwavering commitment to excellence in customer experience and optimal digitisation. The certification process was expertly led by the IT Governance team, with invaluable contributions from various departments, including IS&T. We extend our sincere gratitude to the Information Security team for their critical role in this success. We believe this milestone will further strengthen our capabilities and inspire us to elevate IS&T services to even greater heights.'
ISO certifications are globally recognised as the leading international standards for quality, health and safety, environmental, and facilities management systems. They provide a comprehensive and reliable framework that enhances the ability of organisations to improve operational efficiency, while maintaining the highest global standards through unified and integrated processes.
ISO 27001:2022 is the internationally recognised standard for managing information security risks. It provides a comprehensive framework to establish, implement, maintain, and continuously improve an organisation's information security management system. This certification reinforces NBF's commitment to protecting sensitive information, mitigating cyber threats, and ensuring data security across all business operations.
ISO 9001:2015 is the globally recognised standard for quality management. It sets out the criteria for a robust quality management system, focusing on customer satisfaction, continuous improvement, and process efficiency. Achieving this certification highlights NBF's dedication to maintaining the highest standards of service quality and operational excellence.
Showcasing the bank's commitment to both UAE national quality standards and international best practices, these certifications ensure NBF continues to drive excellence and innovation. The certifications are valid for three years, subject to successful completion of annual surveillance audits.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
See - Sada Elbalad
20 hours ago
- See - Sada Elbalad
New Dialysis Filter Factory Operates in July, Covering 65% of Domestic Demand
H-Tayea A new dialysis filter factory in Egypt is set to begin operations this July, marking a significant step toward self-sufficiency in medical supplies. The plant, built at a cost of EGP 160m, is expected to cover 65% of the country's local demand and generate annual savings of up to EGP 3bn (approximately $50m) by cutting import costs. Amr Abdel Razek, Chairperson of Wadi El Nile Stio and SLS Egypt, announced at a recent press conference that the factory meets the latest international standards and has received ISO certification. He described the project as a strategic initiative aligned with the state's efforts to strengthen domestic healthcare manufacturing capabilities. Currently, the company imports raw materials from Germany, but Abdel Razek revealed plans to fully localize production within a year. This shift is intended to reduce Egypt's dependence on foreign suppliers and reinforce the national healthcare system. Before this development, Egypt imported about 90% of its dialysis filters. The new facility is expected to reverse that trend significantly. In addition to dialysis filters, Wadi El Nile Stio and SLS Egypt are expanding into the production of critical pharmaceutical products, particularly medications used in intensive care, anesthesia, respiration, and cardiology. Abdel Razek noted that 40% of these drugs are already produced locally in compliance with World Health Organization (WHO) standards, with plans to begin exports to neighboring countries to boost foreign currency inflows. To support this industrial expansion, the companies have partnered with German experts to deliver specialized training programs aimed at transferring technology and upskilling local technical teams. Abdel Razek also announced a plan to launch 22 new pharmaceutical products, priced up to 60% lower than imported equivalents. This aligns with government directives to improve access to affordable, high-quality medication. In collaboration with El Nasr Pharmaceutical Chemicals Company, the firms are rehabilitating production lines for anesthetic drugs and plan to develop additional factories to modernize Egypt's pharmaceutical infrastructure. The new dialysis filters and anesthetic products will be supplied to the Egyptian Unified Procurement Authority. Furthermore, the companies aim to establish maintenance centers for dialysis filters across various governorates and launch a dedicated department to service dialysis machines. This factory is the result of agreements signed in June 2023 between El Nasr Pharmaceutical Chemicals Company and Wadi El Nile Stio Life Science for Pharmaceutical Industries to rehabilitate and operate a previously idle facility. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News China Launches Largest Ever Aircraft Carrier Sports Former Al Zamalek Player Ibrahim Shika Passes away after Long Battle with Cancer Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Business Fear & Greed Index Plummets to Lowest Level Ever Recorded amid Global Trade War News Flights suspended at Port Sudan Airport after Drone Attacks Videos & Features Video: Trending Lifestyle TikToker Valeria Márquez Shot Dead during Live Stream News Shell Unveils Cost-Cutting, LNG Growth Plan Technology 50-Year Soviet Spacecraft 'Kosmos 482' Crashes into Indian Ocean News "Tensions Escalate: Iran Probes Allegations of Indian Tech Collaboration with Israeli Intelligence"
Daily News Egypt
2 days ago
- Daily News Egypt
Al Safy Group invests $80m to expand factory in 6th of October City
Al Safy Group is investing $80m to expand its factory in 6th of October City, aiming to increase production capacity and meet rising demand for its high-tech product lines. Global tech giant Xiaomi has chosen the facility to manufacture its smartphones and smart screens—reflecting confidence in Al Safy's industrial capabilities and Egypt's growing competitiveness in the technology sector. Through this strategic partnership, Xiaomi is not only producing its devices in Egypt but also contributing to the country's technological advancement, leveraging Egypt's strategic location and ambitions as a regional hub. Utilising one of the most advanced manufacturing infrastructures in the Middle East and Africa, Xiaomi is integrating global expertise with Egyptian efficiency at the Al Safy factory to produce a range of smart devices. Diaa El Shaarawy, Chief Operating Officer of Al Safy Group, stated: 'Our factory is aligned with the latest global manufacturing technologies through advanced infrastructure and diverse production lines. It currently operates 25 specialised lines, 19 of which are dedicated to Xiaomi. These include six lines for television screens with an annual capacity of 500,000 units, and 12 lines for smartphones with an annual output of up to 3 million units. We also operate a packaging line and are adding new lines for smartwatches, routers, advanced cameras, and headphones—further diversifying our production and responding to growing market needs.' Islam Adel, General Manager of the Al Safy factory, said: 'Al Safy not only keeps pace with global manufacturing standards—it surpasses them in many areas. We adhere to rigorous international quality benchmarks, supported by ORT labs for durability testing, precision testing of components and final products, and compliance with ISO certifications 9001, 14001, and 45001. These all reflect our commitment to excellence.' As Xiaomi's primary manufacturing partner in Egypt and the wider region, Al Safy produces smartphones and smart screens to the same quality standards as those manufactured in China. According to Adel, this localisation strategy has reduced import costs, enhanced the competitiveness of Egyptian-made tech products, and opened up new export markets across Africa and the Arab world through Egypt's trade agreements. Al Safy Group aims to position its facility as a regional industrial hub, capitalising on Egypt's strategic geographic location and broad network of preferential trade agreements. The group continues to increase its investments and expand production lines—reinforcing Egypt's role as a rising force in electronics manufacturing and advanced industries in the region.
Daily News Egypt
2 days ago
- Daily News Egypt
Egypt to launch new dialysis filter factory in July, covering 65% of domestic demand
A new dialysis filter factory in Egypt is set to begin operations this July, marking a significant step toward self-sufficiency in medical supplies. The plant, built at a cost of EGP 160m, is expected to cover 65% of the country's local demand and generate annual savings of up to EGP 3bn (approximately $50m) by cutting import costs. Amr Abdel Razek, Chairperson of Wadi El Nile Stio and SLS Egypt, announced at a recent press conference that the factory meets the latest international standards and has received ISO certification. He described the project as a strategic initiative aligned with the state's efforts to strengthen domestic healthcare manufacturing capabilities. Currently, the company imports raw materials from Germany, but Abdel Razek revealed plans to fully localize production within a year. This shift is intended to reduce Egypt's dependence on foreign suppliers and reinforce the national healthcare system. Before this development, Egypt imported about 90% of its dialysis filters. The new facility is expected to reverse that trend significantly. In addition to dialysis filters, Wadi El Nile Stio and SLS Egypt are expanding into the production of critical pharmaceutical products, particularly medications used in intensive care, anesthesia, respiration, and cardiology. Abdel Razek noted that 40% of these drugs are already produced locally in compliance with World Health Organization (WHO) standards, with plans to begin exports to neighboring countries to boost foreign currency inflows. To support this industrial expansion, the companies have partnered with German experts to deliver specialized training programs aimed at transferring technology and upskilling local technical teams. Abdel Razek also announced a plan to launch 22 new pharmaceutical products, priced up to 60% lower than imported equivalents. This aligns with government directives to improve access to affordable, high-quality medication. In collaboration with El Nasr Pharmaceutical Chemicals Company, the firms are rehabilitating production lines for anesthetic drugs and plan to develop additional factories to modernize Egypt's pharmaceutical infrastructure. The new dialysis filters and anesthetic products will be supplied to the Egyptian Unified Procurement Authority. Furthermore, the companies aim to establish maintenance centers for dialysis filters across various governorates and launch a dedicated department to service dialysis machines. This factory is the result of agreements signed in June 2023 between El Nasr Pharmaceutical Chemicals Company and Wadi El Nile Stio Life Science for Pharmaceutical Industries to rehabilitate and operate a previously idle facility.
